Skip to content

Author

Xing-Jun Huang

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study

Background ALK/ROS1 tyrosine kinase inhibitors (TKIs) have improved outcomes in molecularly selected malignancies, but trial populations do not fully represent the age and clinical heterogeneity encountered in routine care. Comparative post-marketing evidence on age-related and drug-specific reporting patterns remains...

Yong-Jian Liu, Ying-Yuan Yu, Yi-Ge Yu et al. · 0 citations
Open access Sep 2026

Comparative pharmacovigilance of glycaemic adverse-event reporting for alpelisib and capivasertib: A disproportionality analysis of the FDA adverse event monitoring system

Alpelisib and capivasertib inhibit adjacent nodes of the phosphatidylinositol 3-kinase/protein kinase B pathway and disrupt glucose homeostasis. Their overlapping fulvestrant-based treatment contexts support comparison despite different biomarker eligibility. To compare the post-marketing adverse-event repor...

Yong-Jian Liu, Hao Zhong, Xing-Jun Huang et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.